BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

704 related articles for article (PubMed ID: 26482044)

  • 1. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.
    Tang LH; Untch BR; Reidy DL; O'Reilly E; Dhall D; Jih L; Basturk O; Allen PJ; Klimstra DS
    Clin Cancer Res; 2016 Feb; 22(4):1011-7. PubMed ID: 26482044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
    Tang LH; Basturk O; Sue JJ; Klimstra DS
    Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
    Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
    Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Well differentiated grade 3 pancreatic neuroendocrine tumors compared with related neoplasms: A morphologic study.
    Sigel CS; Krauss Silva VW; Reid MD; Chhieng D; Basturk O; Sigel KM; Daniel TD; Klimstra DS; Tang LH
    Cancer Cytopathol; 2018 May; 126(5):326-335. PubMed ID: 29451738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations.
    Elvebakken H; Perren A; Scoazec JY; Tang LH; Federspiel B; Klimstra DS; Vestermark LW; Ali AS; Zlobec I; Myklebust TÅ; Hjortland GO; Langer SW; Gronbaek H; Knigge U; Tiensuu Janson E; Sorbye H
    Neuroendocrinology; 2021; 111(9):883-894. PubMed ID: 33002892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters.
    Crippa S; Partelli S; Bassi C; Berardi R; Capelli P; Scarpa A; Zamboni G; Falconi M
    Surgery; 2016 Mar; 159(3):862-71. PubMed ID: 26602841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survivals of patients with pancreatic neuroendocrine carcinomas: An in-depth analysis by the American Joint Committee on Cancer 8th tumor-node-metastasis staging manual.
    Deng BY; Yang M; Wen JY; Hou SZ; Chen Y; Tian BL; Liu XB; Zhang Y
    Medicine (Baltimore); 2020 Jan; 99(3):e18736. PubMed ID: 32011453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between neuroendocrine carcinomas and well-differentiated neuroendocrine tumors of the pancreas using dynamic enhanced CT.
    Park HJ; Kim HJ; Kim KW; Kim SY; Choi SH; You MW; Hwang HS; Hong SM
    Eur Radiol; 2020 Sep; 30(9):4772-4782. PubMed ID: 32346794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible?
    Grillo F; Albertelli M; Annunziata F; Boschetti M; Caff A; Pigozzi S; Ferone D; Mastracci L
    Endocrine; 2016 Jul; 53(1):58-62. PubMed ID: 26362059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of cytologic differentiation in high-grade pancreatic neuroendocrine neoplasms: A multi-institutional study.
    Sigel CS; Krauss Silva VW; Reid MD; Chhieng D; Basturk O; Sigel KM; Daniel TD; Klimstra DS; Tang LH
    Cancer Cytopathol; 2018 Jan; 126(1):44-53. PubMed ID: 29044913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sporadic Gastric Well-Differentiated Neuroendocrine Tumors Have a Higher Ki-67 Proliferative Index.
    Lee HE; Mounajjed T; Erickson LA; Wu TT
    Endocr Pathol; 2016 Sep; 27(3):259-67. PubMed ID: 27306997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.
    Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M
    Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations in Ki67 Labeling Following Treatment of Poorly Differentiated Neuroendocrine Carcinomas: A Potential Diagnostic Pitfall.
    Vyas M; Tang LH; Rekhtman N; Klimstra DS
    Am J Surg Pathol; 2021 Jan; 45(1):25-34. PubMed ID: 33177340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER Database.
    Punekar SR; Kaakour D; Masri-Lavine L; Hajdu C; Newman E; Becker DJ
    Am J Clin Oncol; 2020 Dec; 43(12):846-849. PubMed ID: 32910023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
    Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
    Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap.
    Klimstra DS; Beltran H; Lilenbaum R; Bergsland E
    Am Soc Clin Oncol Educ Book; 2015; ():92-103. PubMed ID: 25993147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ki-67 cytological index can distinguish well-differentiated from poorly differentiated pancreatic neuroendocrine tumors: a comparative cytohistological study of 53 cases.
    Carlinfante G; Baccarini P; Berretti D; Cassetti T; Cavina M; Conigliaro R; De Pellegrin A; Di Tommaso L; Fabbri C; Fornelli A; Frasoldati A; Gardini G; Losi L; Maccio L; Manta R; Pagano N; Sassatelli R; Serra S; Camellini L
    Virchows Arch; 2014 Jul; 465(1):49-55. PubMed ID: 24807732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An analysis of 130 neuroendocrine tumors G3 regarding prevalence, origin, metastasis, and diagnostic features.
    Kasajima A; Konukiewitz B; Schlitter AM; Weichert W; Klöppel G
    Virchows Arch; 2022 Feb; 480(2):359-368. PubMed ID: 34499237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.